Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | MAOA | P21397 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731619 | 0.81 | MAOB (1.00) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL28471689 | 0.79 | RAB9A (0.60) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL9770341 | 0.78 | MAOB (0.73) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL9051972 | 0.77 | MAOB (0.66) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL107322 | 0.76 | MAOB (0.83) | MAOBNPC1RAB9AMAOAMEN1 | |
| SCHEMBL18253153 | 0.76 | MAOB (0.56) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL16892161 | 0.75 | RAB9A (0.68) | MAOBNPC1RAB9AMAOAKMT2A | |
| SCHEMBL108114 | 0.74 | MAOB (0.74) | MAOBNPC1RAB9AMAOAMEN1 | |
| SCHEMBL6782574 | 0.73 | MAOB (0.65) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL6483452 | 0.73 | MAOB (0.62) | MAOBNPC1RAB9AMAOASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | FAES FARMA, S.A. (ES) | 2013-05-23 | — | — | US | disclosed |
| EP-2576509-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMILOYD PATHOLOGIES | Faes Farma, S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011147780-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMILOYD PATHOLOGIES | FAES FARMA, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| EP-2390248-A1 | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | FAES FARMA, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | APP, MAPT, PSEN1 | MAOB 22/4885NPC1 925/4885RAB9A 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.